The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
Carlson A, Gregorich Z, Striker R. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]
Source
Department of Medicine, University of Wisconsin-Madison.
Abstract
Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.